Friday, February 26, 2021

Study Reveals Ivermectin Highly Effective In Treating Covid: Data 'Overwhelming'


Peer-reviewed study: Ivermectin cuts COVID infections, deaths by 75%




A new, peer-reviewed study finds that one of the cheap, widely available drugs that has been dismissed by the left, establishment media and many in the health establishment as a treatment for COVID-19 reduces infections, hospitalizations and deaths by about 75%.

Ivermectin, in more than 30 trials around the world, causes "repeated, consistent, large magnitude improvements in clinical outcomes’ at all stages of the disease," according to the study, which will be published in the U.S. journal Frontiers of PharmacologyDailyMail.com reported.

The evidence is so strong, the researchers believe, the anti-parasitic drug should become a standard therapy everywhere, hastening global recovery.

"The data is overwhelming – we are in a pandemic, and this is an incredibly effective way to combat it. If we use ivermectin widely, our societies can open up," said study co-author Professor Paul Marik, director of emergency and pulmonary care at Eastern Virginia Medical School.

A previous study by Professor Andrew Hill of Liverpool University also found ivermectin cuts death rates by about 75%.

DailyMail.com said a new trial of ivermectin as a COVID treatment is due to begin soon at Oxford University.


Evidence that the widespread use of ivermectin in parts of India and South America have caused a major reduction in infections and deaths was presented last weekend at an online summit of international experts last weekend hosted by Dr. Tess Lawrie, director of the Evidence-Based Medicine Consultancy in Bath, England.

On Wednesday, Lawrie urged the World Health Organization to recommend ivermectin to treat COVID-19, providing evidence in a 97-page report.

Dr. Harvey Risch, a professor of epidemiology at the Yale School of Public Health and Yale School of Medicine, is one of many health experts who decry the politicization of COVID-19 treatments such as ivermectine and hydroxychloroquine.


"You can hardly believe what anybody says anymore," Risch said in an interview in December with Fox News' Laura Ingraham. "We've lost 300,000 lives in the United States because our government has basic told everyone to go home, stay home, and if you can't breathe, go to the hospital."

That's not a form of treatment, he said, "it's what we call therapeutic nihilism."

He said the federal government, through the FDA, CDC and National Institutes of Health, have misrepresented the benefits of the drugs.

"These are drugs that everywhere else in the world they are being used very effectively," he said.

Risch contends the COVID-19 mortality rate is five times lower in the Third World "because that's all they can afford to do."

"And we're here twiddling our thumbs and telling everyone to stay home. It's absurd," he said.

Ivermectin and hydroxychloroquine were among the outpatient therapies for COVID-19 touted at a Senate hearing in December featuring six prominent physicians who called for removing obstacles to obtaining the drugs, contending they are saving lives, WND reported.


The testimony before the U.S. Senate Committee on Homeland Security and Governmental Affairs on was the second part a hearing organized by Chairman Ron Johnson titled "Early Outpatient Treatment: An Essential Part of a COVID-19 Solution."

In the first hearing, in November, as WND reported, the panel's chairman, Johnson, noted hydroxychloroquine was used as a "weapon" in the presidential election after it was promoted by President Trump.

"The doctors who have had the courage to follow the Hippocratic oath and use their off-label prescription rights to treat patients using hydroxychloroquine have been scorned and state medical boards have threatened to withdraw their licenses," the senator said.

Johnson said he has publicly advocated for "allowing doctors to be doctors, to practice medicine, explore different therapies and share their knowledge within the medical community and with the public."








No comments: